Clinical Trials Logo

Refractory Ovarian Carcinoma clinical trials

View clinical trials related to Refractory Ovarian Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06315491 Not yet recruiting - Clinical trials for Platinum-resistant Ovarian Cancer

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Start date: July 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.